SCHEMBL22308532

SCHEMBL22308532

c1ccc(-c2cc(-c3cccc(-c4cccc(-c5nc(-c6ccccc6)nc(-c6ccccc6)n5)c4)c3)nc(-c3ccc(-c4ccccc4-c4ccccc4)cc3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.61
KMT2A Q03164 9/20 0.61
ALDH1A1 P00352 7/20 0.61
HPGD P15428 7/20 0.61
MAPT P10636 5/20 0.61
KDM4E B2RXH2 4/20 0.61
LMNA P02545 2/20 0.61
GLA P06280 1/20 0.61
NTSR1 P30989 1/20 0.56
ADORA2A P29274 2/20 0.49
ADORA1 P30542 2/20 0.49
MAOB P27338 4/20 0.46
MAOA P21397 3/20 0.46
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPK1 P28482 2/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22308539 1.00 MEN1 (0.61) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL22308533 1.00 MEN1 (0.61) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL22309571 0.97 MEN1 (0.57) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL22308938 0.97 MEN1 (0.57) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL22309406 0.95 MEN1 (0.56) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL22308940 0.95 MEN1 (0.56) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL22310109 0.95 MEN1 (0.56) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL22308923 0.95 MEN1 (0.56) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL22309570 0.95 MEN1 (0.54) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL22309217 0.93 MEN1 (0.58) MEN1KMT2AALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917910-B2 Organic compound and organic electroluminescent device using the same SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2024-02-27 US disclosed
US-11917910-B2 Organic compound and organic electroluminescent device using the same SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2024-02-27 US disclosed
US-20200251659-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME DOOSAN CORPORATION (KR) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200251659-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME VDAC1, OR10J3, PIEZO1 MEN1 2484/4885KMT2A 2549/4885ALDH1A1 644/4885
US-11917910-B2 Organic compound and organic electroluminescent device using the same VDAC1, OR10J3, PIEZO1 MEN1 2484/4885KMT2A 2549/4885ALDH1A1 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.